TY - JOUR
T1 - Capacity for the management of kidney failure in the International Society of Nephrology Latin America region
T2 - report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA)
AU - Regional Board and ISN-GKHA Team Authors
AU - Calice-Silva, Viviane
AU - Neyra, Javier A.
AU - Ferreiro Fuentes, Alejandro
AU - Singer Wallbach Massai, Krissia Kamile
AU - Arruebo, Silvia
AU - Bello, Aminu K.
AU - Caskey, Fergus J.
AU - Damster, Sandrine
AU - Donner, Jo Ann
AU - Jha, Vivekanand
AU - Johnson, David W.
AU - Levin, Adeera
AU - Malik, Charu
AU - Nangaku, Masaomi
AU - Okpechi, Ikechi G.
AU - Tonelli, Marcello
AU - Ye, Feng
AU - Madero, Magdalena
AU - Tzanno Martins, Carmen
AU - Alvarez, Guillermo
AU - Amouzegar, Atefeh
AU - Arellano-Mendez, Denisse
AU - Martinez, Gustavo Aroca
AU - Ferrari, Roger Ayala
AU - Bonano, Carlos
AU - Velarde, Edwin Castillo
AU - Chavez Iñiguez, Jonathan Samuel
AU - Cho, Yeoungjee
AU - Claure-Del Granado, Rolando
AU - Correa-Rotter, Ricardo
AU - Cueto Manzano, Alfonso M.
AU - Cusumano, Ana Maria
AU - Davids, M. Razeen
AU - Davison, Sara N.
AU - Diongole, Hassane M.
AU - Divyaveer, Smita
AU - Ekrikpo, Udeme E.
AU - Ethier, Isabelle
AU - Figueiredo, Ana Elizabeth
AU - Wing-Shing Fung, Winston
AU - Garcia, Guillermo Garcia
AU - Ghimire, Anukul
AU - Gomez, Martin
AU - Gonzalez Bedat, Maria Carlota
AU - Houston, Ghenette
AU - Htay, Htay
AU - Ibrahim, Kwaifa Salihu
AU - Irish, Georgina
AU - Jindal, Kailash
AU - Kelly, Dearbhla M.
N1 - Publisher Copyright:
© 2024 International Society of Nephrology
PY - 2024/4
Y1 - 2024/4
N2 - Successful management of chronic kidney disease (CKD) in Latin America (LA) continues to represent a challenge due to high disease burden and geographic disparities and difficulties in terms of capacity, accessibility, equity, and quality of kidney failure care. Although LA has experienced significant social and economic progress over the past decades, there are still important inequities in health care access. Through this third iteration of the International Society of Nephrology Global Kidney Health Atlas, the indicators regarding kidney failure care in LA are updated. Survey responses were received from 22 of 31 (71%) countries in LA representing 96.5% of its total population. Median CKD prevalence was 10.2% (interquartile range: 8.4%–12.3%), median CKD disability-adjusted life year was 753.4 days (interquartile range: 581.3–1072.5 days), and median CKD mortality was 5.5% (interquartile range: 3.2%–6.3%). Regarding dialysis modality, hemodialysis continued to be the most used therapy, whereas peritoneal dialysis reached a plateau and kidney transplantation increased steadily over the past 10 years. In 20 (91%) countries, >50% of people with kidney failure could access dialysis, and in only 2 (9%) countries, people who had access to dialysis could initiate dialysis with peritoneal dialysis. A mix of public and private systems collectively funded most aspects of kidney replacement therapy (dialysis and transplantation) with many people incurring up to 50% of out-of-pocket costs. Few LA countries had CKD/kidney replacement therapy registries, and almost no acute kidney injury registries were reported. There was large variability in the nature and extent of kidney failure care in LA mainly related to countries’ funding structures and limited surveillance and management initiatives.
AB - Successful management of chronic kidney disease (CKD) in Latin America (LA) continues to represent a challenge due to high disease burden and geographic disparities and difficulties in terms of capacity, accessibility, equity, and quality of kidney failure care. Although LA has experienced significant social and economic progress over the past decades, there are still important inequities in health care access. Through this third iteration of the International Society of Nephrology Global Kidney Health Atlas, the indicators regarding kidney failure care in LA are updated. Survey responses were received from 22 of 31 (71%) countries in LA representing 96.5% of its total population. Median CKD prevalence was 10.2% (interquartile range: 8.4%–12.3%), median CKD disability-adjusted life year was 753.4 days (interquartile range: 581.3–1072.5 days), and median CKD mortality was 5.5% (interquartile range: 3.2%–6.3%). Regarding dialysis modality, hemodialysis continued to be the most used therapy, whereas peritoneal dialysis reached a plateau and kidney transplantation increased steadily over the past 10 years. In 20 (91%) countries, >50% of people with kidney failure could access dialysis, and in only 2 (9%) countries, people who had access to dialysis could initiate dialysis with peritoneal dialysis. A mix of public and private systems collectively funded most aspects of kidney replacement therapy (dialysis and transplantation) with many people incurring up to 50% of out-of-pocket costs. Few LA countries had CKD/kidney replacement therapy registries, and almost no acute kidney injury registries were reported. There was large variability in the nature and extent of kidney failure care in LA mainly related to countries’ funding structures and limited surveillance and management initiatives.
KW - dialysis
KW - economic burden
KW - health care access
KW - kidney disease
KW - kidney replacement therapy
KW - Latin America
UR - http://www.scopus.com/inward/record.url?scp=85189511274&partnerID=8YFLogxK
U2 - 10.1016/j.kisu.2024.01.001
DO - 10.1016/j.kisu.2024.01.001
M3 - Review article
AN - SCOPUS:85189511274
SN - 2157-1724
VL - 13
SP - 43
EP - 56
JO - Kidney International Supplements
JF - Kidney International Supplements
IS - 1
ER -